Zelira Therapeutics Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ZLDAF research report →
Price Chart
About the company
Zelira Therapeutics Limited is an Australian biopharmaceutical company dedicated to the research, development, and commercialization of cannabinoid-derived therapeutic agents, aimed at treating a variety of medical conditions. The firm offers its HOPE brand formulations in Pennsylvania and Louisiana, and is actively developing Zenivol, a cannabinoid-based medicine specifically designed for chronic insomnia. Beyond its prescription products, Zelira also markets several over-the-counter (OTC) items, including SprinJene for oral care and RAF FIVE for dermatological applications.
- CEO
- Oludare Odumosu
- IPO
- 2017
- Employees
- 8
- HQ
- Perth, WA, AU
Get TickerSpark's AI analysis on ZLDAF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $3.42M
- P/E
- -1.56
- PEG
- -0.01
- P/S
- 10020.70
- P/B
- -1.29
- EV/EBITDA
- -2.09
- Div Yield
- 0.00%
- Gross Margin
- -122400.15%
- Op Margin
- -602467.84%
- Net Margin
- -553029.27%
- ROE
- 80.84%
- ROIC
- 128.84%
Latest fiscal year · YoY change
- Revenue
- $656-99.3%
- Gross Profit
- $-802,945-7907.7%
- Op Income
- $-3,952,189
- Net Income
- $-3,627,872+90.1%
- EPS
- $-0.32+90.1%
- OCF Growth
- -11.8%
- FCF Growth
- -11.8%
- 52W High
- $0.42
- 52W Low
- $0.20
- 50D MA
- $0.27
- 200D MA
- $0.33
- Beta
- 0.59
- RSI (14)
- 0
- Avg Volume
- 6
No earnings-call transcripts are available for ZLDAF yet.
- Free Float
- 95.5%
- Shares Outstanding
- 13.15M
- Float Shares
- 12.56M
Our ZLDAF coverage
Recent articles, reports, and earnings notes.
No research on ZLDAF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ZLDAF report →Zelira Therapeutics (OTCMKTS:ZLDAF) and Hyperion DeFi (NASDAQ:HYPD) Critical Analysis
defenseworld.net · Mar 9
Zelira secures transformative US$33 million funding for HOPE® 1 autism program
proactiveinvestors.com · Jan 16
Zelira Therapeutics (OTCMKTS:ZLDAF) Trading Up 13.9% – Here’s Why
defenseworld.net · Dec 30
Zelira Therapeutics (OTCMKTS:ZLDAF) Trading Down 4.4% – Here’s What Happened
defenseworld.net · Dec 4
Zelira Therapeutics well placed to generate further growth in cash flow as commercialisation accelerates
proactiveinvestors.com · Jan 30
Zelira Therapeutics receives A$1.292 million cash R&D tax incentive
proactiveinvestors.com · Jan 11
Zelira Therapeutics receives 25% of US$1 million licensing fee from DRCN Holdings for EDCDM technology
proactiveinvestors.com · Jan 9
Zelira Therapeutics' Phase 1 dose escalation study in chronic pain patients on long-term opioid treatment published in peer-reviewed journal
proactiveinvestors.com · Dec 22
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.